Loading...
Loading...
Goldman Sachs reports that it is adjusting its FY4Q10 EPS estimate for Emerson Electric Company
EMR to $0.80 from $0.84 and its FY2010 estimate to $2.69 from $2.73 for the impact of recent acquisitions and divestitures (Chloride, EMC, LANDesk), which EMR detailed in September.
“At that time, recurring FY2010 EPS guidance moved to $2.50-$2.60 from $2.60-$2.70 to account for $0.05 of full year impact from the Chloride acquisition and $0.05 for the reclassification of EMC to discontinued operations and excluded a one-time $0.18-$0.20 gain on the EMC sale,” Goldman Sachs writes.
“We also tweak our FY2011 EPS estimate to $3.30 from $3.35 for additional Chloride acquisition costs, with no change to recurring revenue or margin assumptions or our fundamental view.”
Goldman Sachs maintains its Neutral rating and $58 (16.6X CY2011E P/E), 12-month price target but says that it continues to have a positive long-term view of the company.
Emerson Electric currently trades for $53.91.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in